Evaluation of RANO response criteria compared to clinician
evaluation in WHO grade III anaplastic astrocytoma:
implications for clinical trial reporting and patterns of
failure

J 2015

Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure

KAZDA, Tomáš; John G. HARDIE; Deanna H. PAFUNDI; Timothy J. KAUFMANN; Debra H. BRINKMANN et al.

Základní údaje

Originální název

Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure

Autoři

KAZDA, Tomáš; John G. HARDIE; Deanna H. PAFUNDI; Timothy J. KAUFMANN; Debra H. BRINKMANN a Nadia N. LAACK

Vydání

Journal of Neuro-Oncology, New York, Springer, 2015, 0167-594X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.754

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083614

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Anaplastic astrocytoma; RANO; Response assessment; Patterns of failure

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 8. 2015 13:51, Jana Dvořáková

Anotace

V originále

The utility of current response criteria has not been established in anaplastic astrocytoma (AA). We retrospectively reviewed MR images for 20 patients with AA and compared RANO-based approaches to clinician impression described as follow: (1) standard RANO-based criteria met by growth of or development of new enhancing lesion (RANO-C), (2) RANO criteria for progression based on significant FLAIR increase (RANO-F) and (3) clinical progression usually resulting in change of treatment (Clinical). Patterns of failure (POF) were analyzed utilizing all proposed progression MRIs fused with the patients' radiotherapy treatment plan. With an overall median survival of 24.3 months, development of new enhancing lesion was the most common determinant of progression (70 % of patients). Median time to RANO-C, RANO-F and Clinical progression was 9.2, 9.2 and 11.76 months respectively. RANO-C and RANO-F preceded Clinical in 70 and 55 % of patients, respectively. In six patients (30 %) Clinical was concurrent with RANO-F; four of six also met RANO-C. POF for FLAIR component differed based on time point used to determine progression. FLAIR POF was more often marginal or distant when progression was defined clinically compared to either RANO-C or RANO-F criteria. Central POF based on FLAIR at Clinical determination of progression was associated with significantly poorer OS (9.8 vs. 34.4 months). Clinical progression occurs later than progression determined by RANO-based criteria. Evaluation of POF based on FLAIR signal abnormality at the time of clinical progression suggests central recurrences are associated with worse survival.

Citovat

KAZDA, Tomáš; John G. HARDIE; Deanna H. PAFUNDI; Timothy J. KAUFMANN; Debra H. BRINKMANN a Nadia N. LAACK. Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. Journal of Neuro-Oncology. New York: Springer, 2015, roč. 122, č. 1, s. 197-203. ISSN 0167-594X. Dostupné z: https://doi.org/10.1007/s11060-014-1703-z.

@article{1309119,
   author = {Kazda, Tomáš and Hardie, John G. and Pafundi, Deanna H. and Kaufmann, Timothy J. and Brinkmann, Debra H. and Laack, Nadia N.},
   article_location = {New York},
   article_number = {1},
   doi = {https://doi.org/10.1007/s11060-014-1703-z},
   keywords = {Anaplastic astrocytoma; RANO; Response assessment; Patterns of failure},
   language = {eng},
   issn = {0167-594X},
   journal = {Journal of Neuro-Oncology},
   title = {Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure},
   volume = {122},
   year = {2015}
}

TY  - JOUR
ID  - 1309119
AU  - Kazda, Tomáš - Hardie, John G. - Pafundi, Deanna H. - Kaufmann, Timothy J. - Brinkmann, Debra H. - Laack, Nadia N.
PY  - 2015
TI  - Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure
JF  - Journal of Neuro-Oncology
VL  - 122
IS  - 1
SP  - 197-203
EP  - 197-203
PB  - Springer
SN  - 0167594X
KW  - Anaplastic astrocytoma
KW  - RANO
KW  - Response assessment
KW  - Patterns of failure
N2  - The utility of current response criteria has not been established in anaplastic astrocytoma (AA). We retrospectively reviewed MR images for 20 patients with AA and compared RANO-based approaches to clinician impression described as follow: (1) standard RANO-based criteria met by growth of or development of new enhancing lesion (RANO-C), (2) RANO criteria for progression based on significant FLAIR increase (RANO-F) and (3) clinical progression usually resulting in change of treatment (Clinical). Patterns of failure (POF) were analyzed utilizing all proposed progression MRIs fused with the patients' radiotherapy treatment plan. With an overall median survival of 24.3 months, development of new enhancing lesion was the most common determinant of progression (70 % of patients). Median time to RANO-C, RANO-F and Clinical progression was 9.2, 9.2 and 11.76 months respectively. RANO-C and RANO-F preceded Clinical in 70 and 55 % of patients, respectively. In six patients (30 %) Clinical was concurrent with RANO-F; four of six also met RANO-C. POF for FLAIR component differed based on time point used to determine progression. FLAIR POF was more often marginal or distant when progression was defined clinically compared to either RANO-C or RANO-F criteria. Central POF based on FLAIR at Clinical determination of progression was associated with significantly poorer OS (9.8 vs. 34.4 months). Clinical progression occurs later than progression determined by RANO-based criteria. Evaluation of POF based on FLAIR signal abnormality at the time of clinical progression suggests central recurrences are associated with worse survival.
ER  -

KAZDA, Tomáš; John G. HARDIE; Deanna H. PAFUNDI; Timothy J. KAUFMANN; Debra H. BRINKMANN a Nadia N. LAACK. Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. \textit{Journal of Neuro-Oncology}. New York: Springer, 2015, roč.~122, č.~1, s.~197-203. ISSN~0167-594X. Dostupné z: https://doi.org/10.1007/s11060-014-1703-z.

Přehled o publikaci